Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Baxter's (BAX) strong product portfolio.

What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?

by Zacks Equity Research

Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

HSIC or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength across its business segments.

CVS Health (CVS) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Strength in all three operating segments drove CVS Health's (CVS) revenues in the fourth quarter of 2021.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Exscientia PLC Sponsored ADR (EXAI) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

by Zacks Equity Research

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Zacks Investment Ideas feature highlights: Henry Schein, AmerisourceBergen and McKesson

by Zacks Equity Research

Henry Schein, AmerisourceBergen and McKesson are included in this Investment Ideas blog.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Bryan Hayes headshot

The Stock-Picking Puzzle: Putting The Pieces Together

by Bryan Hayes

The Stock-Picking Puzzle: Putting The Pieces Together

Here's Why You Should Add Quidel (QDEL) Stock To Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.

Zimmer Biomet (ZBH) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.

Trina Mukherjee headshot

3 Medical Products Stocks Poised to Beat This Earnings Season

by Trina Mukherjee

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.